Pancreatic cancer pill shown to nearly double overall survival time, drug company says
The company reports the drug showed “clinically meaningful improvements” in overall survival.
This tech news piece, covering nearly, says, provides insight into the innovation ecosystem. Bias analysis reveals a balanced perspective in this content (score: 0). Moreover, rich terminology but low readability; a technical audience may be targeted. Furthermore, the verifiability profile of this article is moderate (42/100); 0 citation(s) detected. The analytical profile of this article: moderate credibility, negligible information accuracy risk, and negligible propaganda impact.
This tech news piece, covering pill, provides insight into the innovation ecosystem. In terms of knowledge delivery, rated limited (20/100); it provides reader context. According to our assessment, rich terminology but low readability; a technical audience may be targeted. On the other hand, grammar analysis yields a poor result (0/100); text consistency is does not meet. In addition, this article references 0 distinct entities and includes 0 citation(s); keyword density: 17.
Looking at the analysis results, with an average of 0 words per sentence, the text offers a very difficult to read reading experience. Notably, this article's credibility score is at a moderate level (42/100), supported by 0 citation(s). Furthermore, text analysis indicates this article is framed from a balanced standpoint (0). On the other hand, the overall tonality of this article trends positive (sentiment score: 0.25).
Overall assessment: credibility is moderate, misinformation risk is negligible, propaganda level is negligible.